Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 07:00:36 UTC |
---|
Update Date | 2021-09-26 23:01:14 UTC |
---|
HMDB ID | HMDB0250036 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide |
---|
Description | SCHEMBL6870467 belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene. Based on a literature review very few articles have been published on SCHEMBL6870467. This compound has been identified in human blood as reported by (PMID: 31557052 ). N-[4-[(4as)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | ClC1=C(C=CC(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)=C1)C(=O)N1CC2COCCN2CC2=CC=CC=C12 InChI=1S/C32H28ClN3O3/c33-29-18-24(34-31(37)27-12-6-5-11-26(27)22-8-2-1-3-9-22)14-15-28(29)32(38)36-20-25-21-39-17-16-35(25)19-23-10-4-7-13-30(23)36/h1-15,18,25H,16-17,19-21H2,(H,34,37) |
---|
Synonyms | Not Available |
---|
Chemical Formula | C32H28ClN3O3 |
---|
Average Molecular Weight | 538.04 |
---|
Monoisotopic Molecular Weight | 537.1819195 |
---|
IUPAC Name | N-(3-chloro-4-{13-oxa-1,9-diazatricyclo[9.4.0.0^{3,8}]pentadeca-3,5,7-triene-9-carbonyl}phenyl)-[1,1'-biphenyl]-2-carboxamide |
---|
Traditional Name | N-(3-chloro-4-{13-oxa-1,9-diazatricyclo[9.4.0.0^{3,8}]pentadeca-3,5,7-triene-9-carbonyl}phenyl)-[1,1'-biphenyl]-2-carboxamide |
---|
CAS Registry Number | Not Available |
---|
SMILES | ClC1=C(C=CC(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)=C1)C(=O)N1CC2COCCN2CC2=CC=CC=C12 |
---|
InChI Identifier | InChI=1S/C32H28ClN3O3/c33-29-18-24(34-31(37)27-12-6-5-11-26(27)22-8-2-1-3-9-22)14-15-28(29)32(38)36-20-25-21-39-17-16-35(25)19-23-10-4-7-13-30(23)36/h1-15,18,25H,16-17,19-21H2,(H,34,37) |
---|
InChI Key | TYWBAYRNYLDJBB-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Anilides |
---|
Direct Parent | Benzanilides |
---|
Alternative Parents | |
---|
Substituents | - Benzanilide
- Biphenyl
- Benzodiazepine
- 1,4-benzodiazepine
- Halobenzoic acid or derivatives
- 2-halobenzoic acid or derivatives
- Benzamide
- Benzoic acid or derivatives
- Benzoyl
- Aralkylamine
- Chlorobenzene
- Halobenzene
- Aryl chloride
- Aryl halide
- Morpholine
- Oxazinane
- Vinylogous halide
- Tertiary carboxylic acid amide
- Secondary carboxylic acid amide
- Tertiary amine
- Carboxamide group
- Tertiary aliphatic amine
- Amino acid or derivatives
- Ether
- Dialkyl ether
- Carboxylic acid derivative
- Organoheterocyclic compound
- Azacycle
- Oxacycle
- Organic nitrogen compound
- Amine
- Hydrocarbon derivative
- Organic oxide
- Organic oxygen compound
- Organohalogen compound
- Organochloride
- Organonitrogen compound
- Organooxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredictor | Adduct Type | CCS Value (Å2) | Reference |
---|
DeepCCS | [M-2H]- | 239.196 | 30932474 | DeepCCS | [M+Na]+ | 214.621 | 30932474 |
Predicted Kovats Retention IndicesUnderivatizedMetabolite | SMILES | Kovats RI Value | Column Type | Reference |
---|
N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide | ClC1=C(C=CC(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)=C1)C(=O)N1CC2COCCN2CC2=CC=CC=C12 | 6215.2 | Standard polar | 33892256 | N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide | ClC1=C(C=CC(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)=C1)C(=O)N1CC2COCCN2CC2=CC=CC=C12 | 4525.5 | Standard non polar | 33892256 | N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide | ClC1=C(C=CC(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)=C1)C(=O)N1CC2COCCN2CC2=CC=CC=C12 | 4771.7 | Semi standard non polar | 33892256 |
DerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide,1TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CC=CC=C1C1=CC=CC=C1)C1=CC=C(C(=O)N2CC3COCCN3CC3=CC=CC=C32)C(Cl)=C1 | 4409.5 | Semi standard non polar | 33892256 | N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide,1TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CC=CC=C1C1=CC=CC=C1)C1=CC=C(C(=O)N2CC3COCCN3CC3=CC=CC=C32)C(Cl)=C1 | 4310.4 | Standard non polar | 33892256 | N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide,1TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CC=CC=C1C1=CC=CC=C1)C1=CC=C(C(=O)N2CC3COCCN3CC3=CC=CC=C32)C(Cl)=C1 | 6018.0 | Standard polar | 33892256 | N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CC=CC=C1C1=CC=CC=C1)C1=CC=C(C(=O)N2CC3COCCN3CC3=CC=CC=C32)C(Cl)=C1 | 4621.7 | Semi standard non polar | 33892256 | N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CC=CC=C1C1=CC=CC=C1)C1=CC=C(C(=O)N2CC3COCCN3CC3=CC=CC=C32)C(Cl)=C1 | 4537.4 | Standard non polar | 33892256 | N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CC=CC=C1C1=CC=CC=C1)C1=CC=C(C(=O)N2CC3COCCN3CC3=CC=CC=C32)C(Cl)=C1 | 6018.4 | Standard polar | 33892256 |
|
---|
| MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide 10V, Positive-QTOF | splash10-000i-0000090000-6b3dcc8a1d06c16a778e | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide 20V, Positive-QTOF | splash10-000i-0401090000-4d3c908284b339472554 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide 40V, Positive-QTOF | splash10-0f89-1911020000-12eef67e94714a8c6ba2 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide 10V, Negative-QTOF | splash10-000i-0000090000-011f72aa0f87abd672b9 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide 20V, Negative-QTOF | splash10-001r-5216190000-c677dad72b6ff20062d5 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - N-[4-[(4As)-1,2,4,4a,5,11-hexahydro-[1,4]oxazino[3,4-c][1,4]benzodiazepine-6-carbonyl]-3-chlorophenyl]-2-phenylbenzamide 40V, Negative-QTOF | splash10-0f89-9432430000-b4fae01fcda450d92618 | 2021-10-12 | Wishart Lab | View Spectrum |
|
---|